A 'Major, Major Finding' in Managing Residual Breast Cancer A 'Major, Major Finding' in Managing Residual Breast Cancer

The addition of capecitabine to standard care for HER2-negative breast cancer patients with residual invasive disease after neoadjuvant chemo and surgery improved disease-free and overall survival. Medscape Medical News
Source: Medscape General Surgery Headlines - Category: Surgery Tags: Hematology-Oncology News Source Type: news